Biocryst Pharmaceuticals (BCRX) Income from Continuing Operations (2010 - 2026)

Biocryst Pharmaceuticals has reported Income from Continuing Operations for 17 years, with the latest figure at 721812000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations fell 2255762.5% year-over-year to 721812000.0; the trailing twelve-month figure through Mar 2026 stood at 457983000.0 (down 756.52% YoY), and the FY2025 full-year result was 263861000.0, up 396.87% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 721812000.0, down from 245845000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 245845000.0 in Q4 2025, with the low at 721812000.0 in Q1 2026.
• Historically, Income from Continuing Operations has averaged 60028647.06 across 5 years, with a median of 36149000.0 in 2023.
• Annual changes were most pronounced in 2025 — Income from Continuing Operations surged 1017.5% — and 2026, when it tumbled 2255762.5%.
• Biocryst Pharmaceuticals' Income from Continuing Operations stood at 71541000.0 in 2022, then increased by 13.71% to 61731000.0 in 2023, then surged by 56.59% to 26795000.0 in 2024, then surged by 1017.5% to 245845000.0 in 2025, then tumbled by 393.6% to 721812000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 721812000.0 (Q1 2026), 245845000.0 (Q4 2025), and 12899000.0 (Q3 2025), per Business Quant data.